BBIO

Neil Kumar

Known title: Chief Executive OfficerCIK: 0001742485

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 17, 2026

BridgeBio Reports Inducement Grants and Phase 3 Encaleret Success. BridgeBio Pharma announced it has received inducement grants under Nasdaq Rule 5635(c)(4) and released new data from its Phase 3 CALIBRATE trial for Encaleret. The study showed a 100% improvement in at least one ADH1 symptom and increased bone turnover compared with standard care. Additional real‑world data for Acoramidis demonstrated lower composite risk versus Tafamidis in ATTR‑CM patients. These results support the company’s therapeutic pipeline and may influence investor perception.

this person other insiders at BBIO

Transaction History

BBIO▼ Sell$602K
BBIO▼ Sell$89K
BBIO▼ Sell$679K
BBIO▼ Sell$152K
BBIO▼ Sell$9K
BBIO▼ Sell$154K
BBIO▼ Sell$1.4M
BBIO▼ Sell$1.2M
BBIO▼ Sell$100K
BBIO▲ Buy—
BBIO▼ Sell$2.9M
BBIO▲ Buy—
BBIO▲ Buy—
BBIO▲ Buy—
BBIO▼ Sell$480K
BBIO▼ Sell$573K
BBIO▼ Sell$305K
BBIO▼ Sell$480K
BBIO▼ Sell$573K
BBIO▼ Sell$304K
BBIO▼ Sell$145K
BBIO▼ Sell$95K
BBIO▼ Sell$1.1M
BBIO▼ Sell$31K
BBIO▼ Sell$145K
BBIO▼ Sell$95K
BBIO▼ Sell$1.1M
BBIO▼ Sell$31K
BBIO▼ Sell$152K
BBIO▼ Sell$459K
BBIO▼ Sell$351K
BBIO▼ Sell$793K
BBIO▼ Sell$57K
BBIO▲ Buy—
BBIO▲ Buy—
BBIO▲ Buy—
BBIO▲ Buy—
BBIO▼ Sell$2.4M
BBIO▼ Sell$931K
BBIO▼ Sell$342K
BBIO▼ Sell$65K
BBIO▼ Sell$931K
BBIO▼ Sell$342K
BBIO▼ Sell$65K
BBIO▼ Sell$31K
BBIO▼ Sell$757K
BBIO▼ Sell$570K
BBIO▼ Sell$31K
BBIO▼ Sell$757K
BBIO▼ Sell$570K
BBIO▼ Sell$1.5M
BBIO▼ Sell$1.5M
BBIO▼ Sell$530K
BBIO▼ Sell$395K
BBIO▼ Sell$567K
BBIO▼ Sell$521K
BBIO▼ Sell$382K
BBIO▼ Sell$589K
BBIO▼ Sell$662K
BBIO▼ Sell$713K
BBIO▼ Sell$700K
BBIO▼ Sell$676K
BBIO▼ Sell$982K
BBIO▼ Sell$951K
BBIO▼ Sell$403K
BBIO▼ Sell$21K
BBIO▼ Sell$372K
BBIO▼ Sell$21K
BBIO▼ Sell$1.3M
BBIO▼ Sell$615K
BBIO▼ Sell$44K
BBIO▲ Buy—
BBIO▲ Buy—
BBIO▲ Buy—
BBIO▼ Sell$2.3M
BBIO▼ Sell$552K
BBIO▼ Sell$265K
BBIO▼ Sell$326K
BBIO▼ Sell$293K
BBIO▼ Sell$556K
BBIO▼ Sell$270K
BBIO▼ Sell$320K
BBIO▼ Sell$290K
BBIO▼ Sell$1.0M
BBIO▼ Sell$419K
BBIO▼ Sell$1.0M
BBIO▼ Sell$431K
BBIO▼ Sell$534K
BBIO▼ Sell$816K
BBIO▼ Sell$29K
BBIO▼ Sell$106K
BBIO▼ Sell$464K
BBIO▼ Sell$827K
BBIO▼ Sell$145K
BBIO▼ Sell$163K
BBIO▼ Sell$30K
BBIO▼ Sell$23K
BBIO▼ Sell$848K
BBIO▼ Sell$601K
BBIO▼ Sell$852K
BBIO▼ Sell$605K
BBIO▼ Sell$2.1M
BBIO▼ Sell$128K
BBIO▼ Sell$2.3M
BBIO▲ Buy—
BBIO▼ Sell$552K
BBIO▼ Sell$914K
BBIO▼ Sell$898K
BBIO▼ Sell$569K
BBIO▼ Sell$154K
BBIO▼ Sell$908K
BBIO▼ Sell$427K
BBIO▼ Sell$426K
BBIO▼ Sell$154K
BBIO▼ Sell$907K
BBIO▼ Sell$416K
BBIO▼ Sell$942K
BBIO▼ Sell$364K
BBIO▲ Buy—
BBIO▲ Buy—
BBIO▲ Buy—
BBIO▼ Sell$2.2M
BBIO▼ Sell$764K
BBIO▼ Sell$452K
BBIO▼ Sell$13K
BBIO▼ Sell$748K
BBIO▼ Sell$467K
BBIO▼ Sell$14K
BBIO▼ Sell$791K
BBIO▼ Sell$465K
BBIO▼ Sell$6K
BBIO▼ Sell$788K
BBIO▼ Sell$468K
BBIO▼ Sell$6K
BBIO▼ Sell$1.1M
BBIO▼ Sell$1.1M
BBIO▼ Sell$622K
BBIO▼ Sell$622K
BBIO▼ Sell$473K
BBIO▼ Sell$474K
BBIO▼ Sell$893K
BBIO▼ Sell$119K
BBIO▼ Sell$48K
BBIO▼ Sell$120K
BBIO▼ Sell$898K
BBIO▼ Sell$43K
BBIO▼ Sell$284K
BBIO▼ Sell$743K
BBIO▼ Sell$745K
BBIO▼ Sell$282K
BBIO▼ Sell$1.3M
BBIO▼ Sell$21K
BBIO▲ Buy—
BBIO▼ Sell$1.7M
BBIO▼ Sell$383K
BBIO▼ Sell$541K
BBIO▼ Sell$541K
BBIO▼ Sell$383K
BBIO▼ Sell$306K
BBIO▼ Sell$306K
BBIO▼ Sell$603K
BBIO▼ Sell$603K
BBIO▼ Sell$855K
BBIO▼ Sell$855K
BBIO▼ Sell$73K
BBIO▼ Sell$782K
BBIO▼ Sell$69K
BBIO▼ Sell$778K
BBIO▼ Sell$2.5M
BBIO▼ Sell$858K
BBIO▼ Sell$13K
BBIO▲ Buy—
BBIO▼ Sell$1.1M
BBIO▼ Sell$2.6M
BBIO▼ Sell$2.8M
BBIO▼ Sell$1.3M
BBIO▼ Sell$1.3M
BBIO▼ Sell$1.1M
BBIO▼ Sell$3K
BBIO▲ Buy—
BBIO▼ Sell$837K
BBIO▼ Sell$9.8M
BBIO▼ Sell$147K
BBIO▼ Sell$11.9M
BBIO▼ Sell$0
BBIO▼ Sell$0
BBIO▼ Sell$43K
BBIO▼ Sell$571K
BBIO▲ Buy—
BBIO▼ Sell$668K
BBIO▼ Sell$395K
BBIO▼ Sell$281K
BBIO▲ Buy—
BBIO▼ Sell$687K
BBIO▼ Sell$954K
BBIO▲ Buy—
BBIO▲ Buy—
BBIO▼ Sell$1.8M
BBIO▼ Sell$1.5M
BBIO▼ Sell$6K

We use analytics to understand how market-wall is used. No personal data is sold.